Table 2. Adverse events observed during concomitant phase.
| Toxicity | Grade 1–2, n(%) | Grade 3, n(%) | Grade 4, n(%) | Grade 5, n(%) |
|---|---|---|---|---|
| Haematological-Thrombocytopenia |
1 (6.6%) |
3 (20%) |
2 (13.3%) |
0 |
| Haematological-Lymphopenia |
0 |
1 (6.6%) |
2 (13.3%) |
0 |
| Haematological-Neutropenia |
1 (6.6%) |
1 (6.6%) |
1 (6.6%) |
0 |
| Pulmonary embolism |
0 |
0 |
1 (6.6%) |
0 |
| Cutaneous-Skin rash |
6 (40%) |
0 |
0 |
0 |
| Cutaneous-Hand-foot syndrome |
4 (26.6%) |
2 (13.2 %) |
0 |
0 |
| Dyslipidemia |
1 (6.6%) |
1 (6.6%) |
0 |
0 |
| Diarrhoea |
1 (6.6%) |
1 (6.6%) |
0 |
0 |
| Constipation |
0 |
1 (6.6%) |
0 |
0 |
| Hypertension |
2 (13.3%) |
2 (13.3%) |
0 |
0 |
| Heart rate abnormalities |
4 (26.6%) |
1 (6.6%) |
0 |
0 |
| Fatigue | 3 (20%) | 2 (13.3%) | 0 | 0 |
% are expressed as number of events compared with the entire cohort of patients.